You are here:

Archived: alogliptin (Vipidia)

Advice

following a full submission

alogliptin (Vipidia®) is not recommended for use within NHS Scotland.

Indication under review: For adults aged 18 years and older with type 2 diabetes mellitus to improve glycaemic control in combination with other glucose lowering medicinal products including insulin, when these, together with diet and exercise, do not provide adequate glycaemic control.
Treatment with alogliptin reduces glycosylated haemoglobin, HbA1c, significantly more than placebo when used in combination with metformin or sulfonylurea. There are no clinical studies of alogliptin, as triple therapy, in combination with metformin and sulfonylurea.

The submitting company did not present sufficiently robust clinical and economic analysis to gain acceptance by SMC.

The licence holder has indicated their intention to resubmit.

Drug Details

Drug Name: alogliptin (Vipidia)
SMC Drug ID: 937/14
Manufacturer: Takeda UK Ltd
Indication: For adults aged 18 years and older with type 2 diabetes mellitus to improve glycaemic control in combination with other glucose lowering medicinal products including insulin, when these, together with diet and exercise, do not provide adequate glycaemic control.
BNF Category:
Sub Category: 6.1 Drugs used in diabetes
Submission Type: Full submission
Status: Not Recommended
Date Advice Published: 10 March 2014

Current Advice

Resubmission 13 October 2014

Back